Syndax Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

12.11.24	Syndax Pharmaceuticals Stock Falls After Data From Mid-Stage Study Of Revumenib In Form Of Blood Cancer (Benzinga)
12.11.24	Syndax's Revumenib Trial Reports Positive Data In Relapsed/Refractory MNPM1 AML Patients (RTTNews)
19.09.24	Incyte: Phase 2 Trial Results Of Niktimvo In Chronic Graft-Versus-Host Disease Meet Primary Goal (RTTNews)
29.07.24	Syndax Pharma Says FDA Extended Drug Approval Decision Date For Revumenib By 3 Months (RTTNews)
14.06.24	Syndax Reports Updated Positive Data From Phase 1/2 Combination Trials Of Revumenib (RTTNews)
27.03.24	Syndax Announces FDA Priority Review Of NDA For Revumenib For Treatment Of R/R KMT2Ar Acute Leukemia (RTTNews)
28.02.24	Incyte's Axatilimab Receives FDA Priority Review For Chronic Graft-Versus-Host Disease Treatment (RTTNews)
27.02.24	Syndax Pharmaceuticals: Q4 Earnings Insights (Benzinga)
26.02.24	Earnings Preview: Syndax Pharmaceuticals (Benzinga)
02.01.24	Syndax Announces Presentation at 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire)
02.01.24	Syndax Highlights Recent Updates and Anticipated 2024 Milestones (PR Newswire)
19.12.23	Syndax Announces Closing of Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares (PR Newswire)
15.12.23	Syndax Prices Public Offering Of About 10.8 Mln Shares At $18.50/share (RTTNews)
15.12.23	Syndax Pharma Prices Public Offering Of 10.8 Mln Shares At $18.50/Shr (RTTNews)
15.12.23	Syndax Announces Pricing of $200 Million Public Offering of Common Stock (PR Newswire)
14.12.23	Syndax Announces Proposed $150 Million Public Offering of Common Stock (PR Newswire)
12.12.23	Syndax Presents Positive Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at Late-Breaking Oral Presentation During 65th ASH Annual Meeting (PR Newswire)
11.12.23	Syndax Pharma Reveals Positive Data From Phase 1 Revumenib Combination Trials In Acute Leukemias (RTTNews)
11.12.23	Syndax Announces Positive Data for Revumenib in Patients with Acute Leukemias from the BEAT AML, SAVE AML and AUGMENT-102 Phase 1 Combination Trials (PR Newswire)
04.12.23	Syndax to Host Investor Event to Discuss Axatilimab and Revumenib Data Updates at 65th ASH Annual Meeting (PR Newswire)
21.11.23	Syndax Announces Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Selected as Late-Breaking Presentation at the 65th ASH Annual Meeting (PR Newswire)
07.11.23	Syndax Announces Participation at Stifel Healthcare Conference (PR Newswire)
03.11.23	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
02.11.23	Syndax Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update (PR Newswire)
02.11.23	Syndax Announces Updated Data Supporting Impressive Clinical Profile of Revumenib in Genetically-Defined Acute Leukemias to Be Presented at the 65th ASH Annual Meeting (PR Newswire)
02.11.23	Syndax Announces Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease to Be Featured in Plenary Session at the 65th ASH Annual Meeting (PR Newswire)
26.10.23	Syndax to Announce Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 2, 2023 (PR Newswire)
24.10.23	Syndax to Initiate NDA Submission of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Under FDA's Real-Time Oncology Review Program (PR Newswire)
06.10.23	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
02.10.23	Syndax Pharma AUGMENT-101 Trial Of Revumenib In Acute Leukemia Meets Key Goal (RTTNews)
02.10.23	Syndax Announces Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Meets Primary Endpoint and Stopped Early for Efficacy Following Protocol-Defined Interim Analysis (PR Newswire)
29.09.23	Syndax to Announce Topline Results from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia and Host an Investor Call on October 2, 2023 (PR Newswire)
01.09.23	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
31.08.23	Syndax Announces Participation at the Citi 18th Annual BioPharma Conference (PR Newswire)
04.08.23	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
03.08.23	Syndax Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update (PR Newswire)
25.07.23	Syndax to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 3, 2023 (PR Newswire)
24.07.23	Syndax, Incyte Announce Positive Topline Results From AGAVE-201 Trial Of Axatilimab (RTTNews)
24.07.23	Syndax and Incyte Announce Positive Topline Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease (PR Newswire)
07.07.23	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
02.06.23	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
24.05.23	Syndax Announces Participation at Two Upcoming Investor Conferences (PR Newswire)
08.05.23	Syndax Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update (PR Newswire)
04.05.23	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
01.05.23	Syndax to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 8, 2023 (PR Newswire)
13.04.23	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
07.04.23	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
30.03.23	Syndax Pharmaceuticals Announces Appointment of Neil Gallagher, M.D., Ph.D. as President, Head of Research and Development (PR Newswire)
15.03.23	Syndax Pharmaceuticals Announces Two Publications in Nature of Data from the Phase 1 Portion of AUGMENT-101 in Acute Leukemia Patients (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	295.60	0.96 %	K V
Lonza Grp	531.00	0.53 %	K V
Alcon	76.02	0.34 %	K V
Roche Hldg G	247.40	0.28 %	K V
ABB	48.86	0.27 %	K V
Swisscom	498.40	-0.62 %	K V
UBS Group	26.71	-0.67 %	K V
Zurich Insur Gr	533.00	-0.97 %	K V
Holcim	86.10	-1.01 %	K V
Sika	213.20	-2.47 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Syndax Pharmaceuticals Inc

Aktien Top/Flop

Meistgelesene Nachrichten